Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats

Abstract Background Pioglitazone as a PPAR-g agonist are used for management of type 2 diabetes mellitus. Nevertheless, evidence showed that the therapeutic modulation of PPARg activity using Pioglitazone may be linked with bone mass reduction and fracture risk in type 2 diabetes mellitus patients. The objective of the current research was to inspect the preventive role of some types of probiotic strains including ( Lactobacillus acidophilus , Lactobacillus reuteri , Lactobacillus casei , Bifidiobacterum longum and Bacillus coagulans ) against pioglitazone-induced bone loss. Methods Streptozotocin (60 mg/kg) was administered for diabetes induction. Diabetic rats were fed orally with pioglitazone (300 mg/kg) and probiotics (1×109 CFU/ml/day) alone and in combination of both for 4 weeks. Dual energy X-ray absorptiometry (DEXA) were used to asses BMD, BMC and area of the femur, spine and tibia at the experiment termination. Serum glucose, serum calcium, alkaline phosphatase, phosphorus, BUN, Creatinine, and urine calcium were also analyzed. Results Administration of pioglitazone and probiotics alone and in combination significantly improved elevated blood glucose. Pioglitazone treatment significantly increased urinary calcium and BUN, and decreased ALP and creatinine. Co-treatment of probiotics with pioglitazone significantly decreased urinary calcium, creatinine and ALP. Pioglitazone showed detrimental effects on femur-BMD whereas treatment with probiotics remarkably ameliorated these effects. Among the tested probiotics Bifidiobacterum longum displayed the best protective effects on pioglitazone-induced bone loss in diabetic rats. Conclusion This study suggests probiotic supplementation in diabetic patients on pioglitazone regime could be considering as a good strategy to ameliorate bone loss induced by pioglitazone.

Download Full-text

Protective effects of alkali‐extracted rice protein on diabetic nephropathy in obese type 2 diabetic rats

The FASEB Journal ◽

10.1096/fasebj.27.1_supplement.861.10 ◽

2013 ◽

Vol 27 (S1) ◽

Author(s):

Masatoshi Kubota ◽

Reiko Watanabe ◽

Miki Yamaguchi ◽

Michihiro Hosojima ◽

Akihiko Saito ◽

...

Keyword(s):

Diabetic Nephropathy ◽

Diabetic Rats ◽

Protective Effects ◽

Rice Protein ◽

Type 2 Diabetic

Download Full-text

Protective effects of Pycnogenol® on hyperglycemia-induced oxidative damage in the liver of type 2 diabetic rats

Chemico-Biological Interactions ◽

10.1016/j.cbi.2010.04.023 ◽

2010 ◽

Vol 186 (2) ◽

pp. 219-227 ◽

Cited By ~ 73

Author(s):

Kehkashan Parveen ◽

Mohd. Rashid Khan ◽

Mohd. Mujeeb ◽

Waseem A. Siddiqui

Keyword(s):

Oxidative Damage ◽

Diabetic Rats ◽

Protective Effects ◽

Type 2 Diabetic

Download Full-text

Protective effects of adiponectin on uncoupling of glomerular VEGF–NO axis in early streptozotocin-induced type 2 diabetic rats

International Urology and Nephrology ◽

10.1007/s11255-014-0807-x ◽

2014 ◽

Vol 46 (10) ◽

pp. 2045-2051 ◽

Cited By ~ 10

Author(s):

Ningning Hou ◽

Na Huang ◽

Fang Han ◽

Jiangang Zhao ◽

Xue Liu ◽

...

Keyword(s):

Diabetic Rats ◽

Protective Effects ◽

Type 2 Diabetic

Download Full-text

Protective effects of chronic resveratrol treatment on vascular inflammatory injury in streptozotocin-induced type 2 diabetic rats: Role of NF-kappa B signaling

European Journal of Pharmacology ◽

10.1016/j.ejphar.2013.10.034 ◽

2013 ◽

Vol 720 (1-3) ◽

pp. 147-157 ◽

Cited By ~ 39

Author(s):

Xiaoying Zheng ◽

Shenyin Zhu ◽

Shufang Chang ◽

Yanni Cao ◽

Jie Dong ◽

...

Keyword(s):

Diabetic Rats ◽

Protective Effects ◽

Nf Kappa B ◽

Inflammatory Injury ◽

Resveratrol Treatment ◽

Type 2 Diabetic

Download Full-text

Protective Effects of Celastrol on Diabetic Liver Injury via TLR4/MyD88/NF-κB Signaling Pathway in Type 2 Diabetic Rats

Journal of Diabetes Research ◽

10.1155/2016/2641248 ◽

2016 ◽

Vol 2016 ◽

pp. 1-10 ◽

Cited By ~ 29

Author(s):

Li-ping Han ◽

Chun-jun Li ◽

Bei Sun ◽

Yun Xie ◽

Yue Guan ◽

...

Keyword(s):

Liver Injury ◽

Signaling Pathway ◽

Diabetic Rats ◽

Inflammatory Factors ◽

Hepatic Tissue ◽

Control Group ◽

Dependent Manner ◽

Protective Effects ◽

Type 2 Diabetic

Immune and inflammatory pathways play a central role in the pathogenesis of diabetic liver injury. Celastrol is a potent immunosuppressive and anti-inflammatory agent. So far, there is no evidence regarding the mechanism of innate immune alterations of celastrol on diabetic liver injury in type 2 diabetic animal models. The present study was aimed at investigating protective effects of celastrol on the liver injury in diabetic rats and at elucidating the possible involved mechanisms. We analyzed the liver histopathological and biochemical changes and the expressions of TLR4 mediated signaling pathway. Compared to the normal control group, diabetic rats were found to have obvious steatohepatitis and proinflammatory cytokine activities were significantly upregulated. Celastrol-treated diabetic rats show reduced hepatic inflammation and macrophages infiltration. The expressions of TLR4, MyD88, NF-κB, and downstream inflammatory factors IL-1βand TNFαin the hepatic tissue of treated rats were downregulated in a dose-dependent manner. We firstly found that celastrol treatment could delay the progression of diabetic liver disease in type 2 diabetic rats via inhibition of TLR4/MyD88/NF-κB signaling cascade pathways and its downstream inflammatory effectors.

Download Full-text

Genistein prevents bone loss in type 2 diabetic rats induced by streptozotocin

Food & Nutrition Research ◽

10.29219/fnr.v64.3666 ◽

2020 ◽

Vol 64 ◽

Author(s):

Rongrong Lu ◽

Zicong Zheng ◽

Yimin Yin ◽

Zhuoqin Jiang

Keyword(s):

Bone Loss ◽

Diabetic Rats ◽

Type 2 Diabetic

Download Full-text

Probiotics Ameliorate Pioglitazone-associated Bone Loss in Diabetic Rats

10.21203/rs.3.rs-32789/v1 ◽

2020 ◽

Author(s):

Ahmad Gholami ◽

Mohammad Hossein Dabbaghmanesh ◽

Younes Ghasemi ◽

Pedram Talezadeh ◽

Farhad Koohpeyma ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Bone Loss ◽

Lactobacillus Reuteri ◽

Diabetic Rats ◽

Urinary Calcium ◽

Diabetic Patients ◽

Protective Effects

Abstract Background: Pioglitazone as a PPAR-g agonist are used for management of type 2 diabetes mellitus. Nevertheless, evidence showed that the therapeutic modulation of PPARg activity using Pioglitazone may be linked with bone mass reduction and fracture risk in type 2 diabetes mellitus patients. The objective of the current research was to inspect the preventive role of some types of probiotic strains including (Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus casei, Bifidiobacterum longum and Bacillus coagulans) against pioglitazone-induced bone loss.Methods: Streptozotocin (60 mg/kg) was administered for diabetes induction. Diabetic rats were fed orally with pioglitazone (300 mg/kg) and probiotics (1×109 CFU/ml/day) alone and in combination of both for 4 weeks. Dual energy X-ray absorptiometry (DEXA) were used to asses BMD, BMC and area of the femur, spine and tibia at the experiment termination. Serum glucose, serum calcium, alkaline phosphatase, phosphorus, BUN, Creatinine, and urine calcium were also analyzed. Results: Administration of pioglitazone and probiotics alone and in combination significantly improved elevated blood glucose. Pioglitazone treatment significantly increased urinary calcium and BUN, and decreased ALP and creatinine. Co-treatment of probiotics with pioglitazone significantly decreased urinary calcium, creatinine and ALP. Pioglitazone showed detrimental effects on femur-BMD whereas treatment with probiotics remarkably ameliorated these effects. Among the tested probiotics Bifidiobacterum longum displayed the best protective effects on pioglitazone-induced bone loss in diabetic rats.Conclusion:This study suggests probiotic supplementation in diabetic patients on pioglitazone regime could be considering as a good strategy to ameliorate bone loss induced by pioglitazone.

Download Full-text